Reports Q4 adjusted EBITDA $5.9M vs. $100,000 last year. “FY24 was a transformative year where our entire team delivered on multiple fronts,” said Beena Goldenberg, CEO. “We received significant funding from BAT when capital for the cannabis industry was scarce. We made smart, strategic investments, including into seed-based technology and automation, which is increasing efficiency. We have also expanded our international footprint through a $21M investment in Sanity Group, a leading German cannabis company, as well as through several new supply agreements to provide products to patients in Australia and the UK. As we integrate recently-acquired Motif into the Organigram (OGI) ecosystem, we head into FY25 as Canada’s #1 LP and we are very excited for the next phase of our growth plans focused on efficiency, consumer-centric innovation, and international expansion.”
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OGI:
- Organigram Acquires Motif Labs, Becomes Canada’s Largest Cannabis Company
- Options Volatility and Implied Earnings Moves This Week, December 16 – December 20, 2024
- Rising High: Organigram acquires Motif Labs for C$90M upfront
- Organigram to Announce Q4 and Fiscal 2024 Results
- Organigram price target lowered to C$3.15 from C$3.60 at Canaccord